Abstract
Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
Keywords: anticancer treatment; immunogenicity; mRNA-based vaccination; seroconversion; solid cancer.
【저자키워드】 immunogenicity, Seroconversion, anticancer treatment, mRNA-based vaccination, solid cancer., 【초록키워드】 Treatment, vaccination, immunogenicity, therapy, antibody, SARS-CoV-2 vaccine, COVID-19 disease, adverse events, serum, Seroconversion, mRNA, Patient, Cancer patients, Immune checkpoint inhibitor, Mild, antibody levels, patients, severe COVID-19 disease, SARS-CoV-2 vaccination, antibody level, Immune checkpoint inhibitors, solid cancer, cancer patient, active treatment, Adverse, second dose, participant, healthy controls, seroconversion rate, anticancer, mRNA-based vaccine, Complete, Prevent, event, anti-SARS-CoV-2 S1 IgG, Course, Result, receiving, A significant reduction, mRNA-based, 【제목키워드】 cancer patient, severe adverse event, Solid,